Nataliia Morska

Nataliia Morska

Auto-generated profile, based on publicly available information

Nataliia Morska

SE “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the National Academy of Medical Sciences of Ukraine”, M. Amosova St., 10, Kyiv, 03038

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Volodymyr GavrysyukVolodymyr Gavrysyuk
Volodymyr Gavrysyuk
IMIevgeniia Merenkova
Ievgeniia Merenkova
YDYaroslav Dziublyk
Yaroslav Dziublyk
NMNataliia Morska
Nataliia Morska
NPNataliia Pendalchuk
Nataliia Pendalchuk
NVNataliia Vlasova
Nataliia Vlasova
Background: There is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate. Purpose: The aim of our study was to evaluate primary and long-term outcomes of using MTX and MP in patients with pulmonary sarcoidosis. Methods: A total of 143 patients with newly diagnosed pulmonary sarcoidosis, verified by high-resolution computed tomography (CT) data, were examined. Corticosteroid (CS) therapy was used in 97 patients using MP at a dose of 0.4 mg/kg body weight for 4 weeks, followed by a dose reduction to 0.1 mg/kg by the end of the sixth month. The total duration of CS therapy was 12 months on average. Forty-six patients were treated with MTX at a dose of 10 mg/week (28) and 15 mg/week (18) per os for 6 to 12 months. The study of the relapse rate was conducted within 12 months after the CT data normalization in 60 patients after CS therapy and in 24 after MTX treatment. Results: MP treatment was successfully completed in 68 (70.1%), and MTX in 29 (60.4%) patients. In five MP patients (5.2%) and in five (10.9%) MTX, treatment was discontinued due to serious side effects. In seven (7.2%) MP patients and ten (21.7%) MTX patients, treatment required additional therapy due to the lack of efficacy. Progression with MP treatment (17–17.5%) was more common than with MTX (2–4.3%; Chi square = 4.703, p = 0.031). Relapses after MP therapy were observed in 26 (43.3%) patients, and after MTX therapy in 2 (8.3%; Chi square = 9.450, p = 0.003). Conclusion: In patients with pulmonary sarcoidosis, MTX monotherapy does not differ significantly from MP monotherapy in terms of the level of efficacy and the rate of serious side effects. Increasing the MTX dose from 10 to 15 mg/week accelerates the rate of regression of sarcoidosis, improves treatment efficacy, and does not affect the rate of serious side effects. When using MTX, there is a significant decrease in the incidence of treatment resistance and the relapse rate.

20 December 2021 in Medicni perspektivi
Verified
Journal Article
Open access
PDF file
Volodymyr GavrysyukVolodymyr Gavrysyuk
Volodymyr Gavrysyuk
IMIevgeniia Merenkova
Ievgeniia Merenkova
GGG.L. Gumeniuk
G.L. Gumeniuk
NPN.V. Pendalchuk
N.V. Pendalchuk
NMN.D. Morska
N.D. Morska
NVN.A. Vlasova
N.A. Vlasova
The objective of this study is to conduct a comparative study of the efficacy and safety of methotrexate (MT) at a dose of 10 mg/week and 15 mg/week in patients with pulmonary sarcoidosis having contraindications to GCS therapy. Material and Methods. The study involved 44 patients with stage II pulmonary sarcoidosis (26 females and 18 males aged 24 to 70) with contraindications to the appointment of therapy glucocorticosteroid (GCS). In group 1 (28 patients), methotrexate was prescribed at a dose of 10 mg/week, in group 2 (16 patients), methotrexate was prescribed at a dose of 15 mg/week. The diagnosis and assessment of the dynamics of sarcoidosis were carried out taking into account clinical symptoms based on the results of high-resolution computed tomography and body plethysmography. The significance of differences in indicators was determined using the Student's t-test and Fisher's exact test. The number of cases of clinical treatment without residual changes of a fibrous nature in the lung parenchyma in patients after treatment with methotrexate at a dose of 15 mg/week significantly increased compared to the same indicator in the group of patients after treatment at a dose of 10 mg/week (81.3% and 42.4% respectively, p=0.025). An increase in the therapeutic dose of methotrexate from 10 mg/week to 15 mg/week leads to a decrease in the time to achieve a clinical cure (10.1±0.5 months and 12.8±0.8 months respectively, р˂0.02), indicating an accelerating rate of regression of sarcoidosis. Immunosuppressive therapy of patients with pulmonary sarcoidosis using the drug at doses of 10 and 15 mg/week is characterized by satisfactory tolerability.

1 January 2021 in Ukrainian Pulmonology Journal
Verified
Journal Article
Open access
VGV. K. Gavrysyuk
V. K. Gavrysyuk
NUNational institute of phthisiology and pulmonology named after F. G. Yanovsky NAMS of Ukraine
National institute of phthisiology and pulmonology named after F. G. Yanovsky NAMS of Ukraine
YDYaroslav Dziublyk
Yaroslav Dziublyk
IMI. O. Merenkova
I. O. Merenkova
GGG. L. Gumeniuk
G. L. Gumeniuk
SLS. I. Leshchenko
S. I. Leshchenko